Dr. Nagasaka presented Case 1, a 63-year-old with EGFR-mutant stage IIB NSCLC highlighted adjuvant chemo plus osimertinib and debate on continuing therapy beyond three years. Dr. Iams presented Case 2, a 64-year-old with large lung adenocarcinoma revealed rare EZH1 fusion on NGS; panel favored trials or targeted therapy given high recurrence risk. Dr. Doroshow reviewed Case 3, a 60-year old woman who showed early-stage lung adenocarcinoma treated with neoadjuvant IO and surgery, later recurring. Discussion stressed EGFR biology, MRD testing, and role of radiation. Dr. Rodriguez presented Case 4, a 46-year-old with stage IIIB BRAF-mutant NSCLC showed major pathologic response after chemo; panel favored adjuvant immunotherapy and discussed local control.